Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with chemotherapy-na? recurrent or metastatic malignant melanoma was recently completed. In Stage 1 of this two-stage clinical trial, 17 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria. This trial was designed to require at least 1 confirmed partial response in 15 patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 6 of 17 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib for the treatment of hormone refractory prostate cancer who had failed taxane-based chemotherapy was recently completed. In Stage 1 of this two-stage clinical trial, 21 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria and a prostate-specific antigen (PSA) response of a greater than 50% decline confirmed 3 weeks later. This trial was designed to require a minimum of 1 PSA response in the first 20 evaluable patients in Stage 1 in order to proceed to Stage 2. No patient met the criteria for a PSA response and the median time to PSA or clinical progression was 9 weeks. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the next stage in the clinical trial. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscrip
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:3/5/2015)... 2015   AMC Health , the leading ... improving the effectiveness and efficiency of healthcare for ... and Jared Wilstead have joined ... Strategic Client Development, and Wilstead will serve as ... Health,s commitment to accelerating the adoption of monitored ...
(Date:3/5/2015)... 5, 2015  AMRI (NASDAQ: AMRI ) ... newly created position of VP of International Sales, effective ... Vice President of Global Sales and Marketing. ... international sales team in an effort to increase worldwide ... segments. Mr. Pettersson will drive strategy for sales and ...
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, Inc. ... that it has acquired the approved abbreviated new ... 50mg, 100mg and 150mg, previously marketed by Teva ... for this product was approximately $39 million in ... , President and CEO of ANI Pharmaceuticals, stated, ...
Breaking Medicine Technology:AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3AMRI Hires VP of International Sales 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... Current family planning,use prevents over one million ... to further reduce the number of infants born ... Reports, "Family Planning,Choices for Women With HIV," published ... of Public Health, Center for Communication Programs. ...
... Coalition unites women in joining the fight for, education and ... ... cancer, WASHINGTON, Sept. 21 More than 80 women and,men ... Washington,D.C. to attend the First Annual Cervical Cancer/HPV Conference, conducted,by the ...
Cached Medicine Technology:Hopkins Report: Focusing on Family Planning Lessens HIV Impact 2Hopkins Report: Focusing on Family Planning Lessens HIV Impact 3The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy 2The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy 3The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy 4
(Date:3/5/2015)... (PRWEB) March 06, 2015 In 2014, ... being first–in-class. AstraZeneca tops the list scoring 4 drug ... over 25% of all FDA approved drug products, followed ... mechanisms such as anti-PCSK9, anti-PD1 and CDK inhibitors keep ... approved by the FDA to treat metastatic melanoma, and ...
(Date:3/5/2015)... CA (PRWEB) March 05, 2015 ... of formaldehyde in low-cost laminate flooring products, ... leading manufacturer of eco-friendly building materials made primarily ... safety by testing all their flooring products for ... detection laboratory Benchmark International (BMH). Results ...
(Date:3/5/2015)... 05, 2015 Risperdal lawsuits ( ... Pennsylvania mass tort litigation currently underway in the ... has begun hearing testimony in the proceeding’s second ... medication can cause gynecomastia, or male breast growth. ... was filed on behalf of a plaintiff who ...
(Date:3/5/2015)... RI (PRWEB) March 05, 2015 Rhode Island ... third year in a row to support the Providence College ... The donation covered the purchase of the ‘Think Pink’ uniforms, ... against Big East Conference opponent DePaul University at Alumni Hall/Mullaney ... to continue our support of the PC women’s basketball’s ‘Pink ...
(Date:3/5/2015)... 05, 2015 On March 2, 2015, ... Labiaplasty on the Rise, Plastic Surgeons Say,” that comments ... Society for Aesthetic Plastic Surgery and the ... reported a year-over-year doubling of surgical butt augmentations performed ... in the article, this increase can be attributed to ...
Breaking Medicine News(10 mins):Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2
... 2 The Medical University of,South Carolina Hollings ... Foundation to create the Countess Alicia Paolozzi,Distinguished Endowed ... Cancer Center will provide matching funds of $500,000,for ... will allow Hollings Cancer Center to recruit an,outstanding ...
... 2 , WHAT: Now that Congress has made important progress toward reauthorizing ... the American Health Care Association (AHCA) ... the aisle to focus on quality long term care for our nation,s ... BDO Seidman, LLP and Eljay, LLC are releasing ...
... May Help Reduce Risk of ... Elevated Inflammation in Blood Vessels, WATSONVILLE, Calif., Oct. ... research from Harvard Medical School found,that they may offer ... reported eating the most strawberries experienced lower,blood levels of ...
... Overall ... Laboratory Workflow, TARRYTOWN, ... announced today,worldwide availability of version 2.0 software for the Rapidlab ... required upgrade for,all existing customers and included on all Rapidlab ...
... Neuroscientists at Vanderbilt University are stepping into the ... O. Conte Center for Neuroscience Research., The new ... the National Institute of Mental Health (NIMH), will ... networks that control serotonin systems in the brain., ...
... Mylan Inc. (NYSE: MYL ),today announced the ... charge of Global Technical Operations. Mr. Malik has ... Company acquired a controlling stake in Matrix,Laboratories Limited ... 2007. As Head of Global Technical Operations, ...
Cached Medicine News:Health News:Hollings Cancer Center Creates $1 Million Endowed Chair for Breast Cancer Research and Treatment with Gift from the Spaulding-Paolozzi Foundation 2Health News:New Study Finds Medicaid Under-Funds Long Term Care by $4.4 Billion Annually 2Health News:Strawberry Consumption Associated with C-Reactive Protein Among Women: New Harvard Study 2Health News:Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software 2Health News:Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software 3Health News:Vanderbilt nets brain gene research center 2Health News:Vanderbilt nets brain gene research center 3Health News:Mylan Appoints Rajiv Malik as Executive Vice President, Head of Global Technical Operations 2
... Estriol (E3) is one of the 3 ... estradiol and estrone). In terms of estrogenic ... estradiol [1]. Estriol is produced almost exclusively ... produced in the normal human fetus. During ...
... Estrone Sulfate (E1S) is the most abundant ... as normal men [1,2]. Estrone Sulfate is ... and has a longer half-life in blood ... generally parallel those of estrone and estradiol, ...
Helmer's Horizon Series line of refrigerators are designed specifically for the cost conscious buyer. This line offers outstanding performance, quality, and the features you need to ensure the safety...
... the i.Series refrigerator iB120, ... for the blood bank. ... than ever before, i.Series ... at the forefront of ...
Medicine Products: